/RHHBY
RHHBY Stock - Roche Holding AG
Healthcare|Drug Manufacturers - GeneralOTC
$53.34+0.26%
+$0.14 (+0.26%) • Jan 13
76
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.BUY
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.95
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).64
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.100
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+6.9%upside
Target: $57.02
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for RHHBY
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$52.81 – $53.87
TARGET (TP)$57.00
STOP LOSS$49.07
RISK/REWARD1:0.9
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta0.17
52W High$53.90
52W Low$34.75
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $62.40B | $60.44B | $65.81B | $62.80B | $58.32B |
| Gross Profit | $46.11B | $44.84B | $44.44B | $43.10B | $41.97B |
| Gross Margin | 73.9% | 74.2% | 67.5% | 68.6% | 72.0% |
| Operating Income | $13.42B | $15.39B | $17.48B | $17.28B | $18.54B |
| Net Income | $8.28B | $11.50B | $12.42B | $13.93B | $14.29B |
| Net Margin | 13.3% | 19.0% | 18.9% | 22.2% | 24.5% |
| EPS | $1.30 | $1.80 | $1.94 | $2.05 | $2.09 |
Company Overview
Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Switzerland, Germany, the United States, Austria, Netherlands, the United Kingdom, France, Belgium, and internationally. The company offers pharmaceutical products for treating oncology, neuroscience, infectious, immunology, cardiovascular and metabolism, ophthalmology, and respiratory, as well as anemia, cancer, dermatology, hemophilia, inflammatory and autoimmune, neurological, and transplantation. It also offers in vitro tests for the diagnosis of various diseases, such as cancer, diabetes, Covid-19, hepatitis, human papillomavirus, and other diseases. In addition, the company supplies diagnostic instruments and reagents. The company was founded in 1896 and is headquartered in Basel, Switzerland.
Visit WebsiteLoading analyst ratings...
Earnings History & Surprises
RHHBYBeat Rate
19%
Last 16 quarters
Avg Surprise
-17.1%
EPS vs Estimate
Beats / Misses
3/13
Last 12 quarters
Latest EPS
$1.74
Q3 2025
EPS Surprise History
Q1 23
-4.2%
$1.14vs$1.19
Q2 23
-16.8%
$1.24vs$1.49
Q3 23
-2.7%
$1.45vs$1.49
Q4 23
-35.1%
$0.79vs$1.22
Q2 24
-16.2%
$1.09vs$1.30
Q4 24
-70.4%
$0.35vs$1.17
Q2 25
-55.2%
$0.73vs$1.62
Q3 25
+7.4%
$1.74vs$1.62
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q1 2026 | Jan 29, 2026 | — | — | — | — |
Q3 2025 | Jul 24, 2025 | $1.62 | $1.74 | +7.4% | ✓ BEAT |
Q2 2025 | Jun 30, 2025 | $1.62 | $0.73 | -55.2% | ✗ MISS |
Q4 2024 | Dec 31, 2024 | $1.17 | $0.35 | -70.4% | ✗ MISS |
Q4 2024 | Oct 23, 2024 | — | — | — | — |
Q2 2024 | Jun 29, 2024 | $1.30 | $1.09 | -16.2% | ✗ MISS |
Q2 2024 | Apr 26, 2024 | — | — | — | — |
Q4 2023 | Dec 31, 2023 | $1.22 | $0.79 | -35.1% | ✗ MISS |
Q4 2023 | Nov 29, 2023 | — | — | — | — |
Q3 2023 | Jul 27, 2023 | $1.49 | $1.45 | -2.7% | ✗ MISS |
Q2 2023 | Jun 30, 2023 | $1.49 | $1.24 | -16.8% | ✗ MISS |
Q1 2023 | Feb 2, 2023 | $1.19 | $1.14 | -4.2% | ✗ MISS |
Q4 2022 | Dec 31, 2022 | $1.19 | $0.66 | -44.7% | ✗ MISS |
Q3 2022 | Jul 21, 2022 | $1.41 | $1.52 | +7.8% | ✓ BEAT |
Q2 2022 | Jun 30, 2022 | $1.41 | $1.37 | -2.8% | ✗ MISS |
Q1 2022 | Feb 3, 2022 | $1.32 | $1.26 | -4.5% | ✗ MISS |
Q4 2021 | Dec 31, 2021 | $1.32 | $0.98 | -26.0% | ✗ MISS |
Q3 2021 | Jul 22, 2021 | $1.38 | $1.44 | +4.3% | ✓ BEAT |
Q2 2021 | Jun 30, 2021 | $1.38 | $1.22 | -11.6% | ✗ MISS |
Q1 2021 | Feb 1, 2021 | $1.24 | $1.21 | -2.4% | ✗ MISS |
Latest News
Loading news...
Frequently Asked Questions about RHHBY
What is RHHBY's current stock price?
Roche Holding AG (RHHBY) is currently trading at $53.34 per share. The stock has moved +0.26% today.
What is the analyst price target for RHHBY?
The average analyst price target for RHHBY is $57.00, based on 1 analyst.
What sector is Roche Holding AG in?
Roche Holding AG operates in the Healthcare sector, specifically within the Drug Manufacturers - General industry. The company is traded on the OTC exchange.
What is RHHBY's market cap?
Roche Holding AG has a market capitalization of $339.88 billion, making it a mega-cap company.
Does RHHBY pay dividends?
No, Roche Holding AG does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorAZNCF
AstraZeneca PLC
$188.66
Mkt Cap: $292.5B
CHGCF
Chugai Pharmaceutical Co., Ltd.
$54.13
Mkt Cap: $89.1B
CHGCY
Chugai Pharmaceutical Co., Ltd.
$26.51
Mkt Cap: $87.3B
DSKYF
Daiichi Sankyo Company, Limited
$22.26
Mkt Cap: $41.2B
DSNKY
Daiichi Sankyo Company, Limited
$22.33
Mkt Cap: $41.7B
GLAXF
GSK plc
$25.00
Mkt Cap: $100.7B
NONOF
Novo Nordisk A/S
$58.78
Mkt Cap: $261.3B
NVSEF
Novartis AG
$137.66
Mkt Cap: $264.1B
SNYNF
Sanofi
$95.53
Mkt Cap: $116.4B
SRTOY
Sartorius Stedim Biotech S.A.
$26.54
Mkt Cap: $258.2B
Explore stocks similar to RHHBY for comparison